Table 2. Comparison of objective response rate and progression free survival of EGFR mutant treatment naïve (LUX-LUNG 3), post-gefitinib (NOS) (IMPRESS), post-gefitinib plasma T790M-positive or negative (IMPRESS) and the AURA 3 population receiving platinum-pemetrexed (3,11,20,21).

Endpoint	LUX-LUNG 3 (EGFR TKI naïve) (n=115)	IMPRESS (post-gefitinib, NOS) (n=132)	IMPRESS (post-gefitinib, plasma T790M+) (n=61)	IMPRESS (post-gefitinib, plasma T790M- negative) (n=31)	AURA 3 (n=140)
Objective response rate	23%	34%	39%	32%	31%
Median PFS	6.9 months	5.4 months	5.3 months	4.6 months	4.4 months